Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-CAR028 in Relapsed/Refractory AML
NCT07198867Phase 1Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of A-CAR028 in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days and Treatment Emergent Adverse Events at 3 months. Started Sep 2025; status: recruiting.
02
Drugs
A-CAR028
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07198867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07198867.